Left ventricular dysfunction: causes, natural history, and hopes for reversal.
Armstrong
P W
PW
Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D003327:Coronary Disease / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006321:Heart / Q000503:physiopathology; D006333:Heart Failure / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D013148:Spironolactone / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D020257:Ventricular Remodeling
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D002216:Captopril